HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch

STAT+: Pharmalittle: We’re reading about a review of Alzheimer’s drugs, FDA interest in compounded peptides, and more

The FDA will convene an outside panel of advisers to discuss whether to allow compounding pharmacies to manufacture certain peptides

By STAT News · Apr 16, 2026 · via STAT News
STAT+: Pharmalittle: We’re reading about a review of Alzheimer’s drugs, FDA interest in compounded peptides, and more

Image: STAT News

Tags
theweekformat:headlineheadlineSTAT News
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
Opinion: The podcast bringing together MAHA and public health for hard conversations
The WeekSTAT News ↗
“These sides aren't talking to each other. And there's a lot riding on it”: The hosts of “Why Should I Trust Y…
Apr 18, 2026
KFF Unveils “The Business of Health” Podcast with Chip Kahn
The WeekBriefing
KFF’s new weekly podcast debuts April 2026, diving into healthcare’s financial and policy mechanics, starting …
Apr 17, 2026
Vertical Integration Bends MLR Rules as Copay Maximizers Expand
The WeekBriefing
Drug Channels’ April roundup highlights how vertical integration and copay maximizers are changing the economi…
Apr 17, 2026